Search by Drug Name or NDC
NDC 50090-1693-09 IPOL 40; 8; 32 [D'ag'U]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL Details
IPOL 40; 8; 32 [D'ag'U]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL
IPOL is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by A-S Medication Solutions. The primary component is POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED); POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED); POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED).
MedlinePlus Drug Summary
Why get vaccinated? Polio vaccine can prevent polio. Polio (or poliomyelitis) is a disabling and lifethreatening disease caused by poliovirus, which can infect a person's spinal cord, leading to paralysis. Most people infected with polio have no symptoms, and many recover without complications. Some people will experience sore throat, fever, tiredness, nausea, headache, or stomach pain. A smaller group of people will develop more serious symptoms that affect the brain and spinal cord: Paresthesia (feeling of pins and needles in the legs), Meningitis (infection of the covering of the spinal cord and/or brain), or Paralysis (can't move parts of the body) or weakness in the arms, legs, or both. Paralysis is the most severe symptom associated with polio because it can lead to permanent disability and death. Improvements in limb paralysis can occur, but in some people new muscle pain and weakness may develop 15 to 40 years later. This is called "post-polio syndrome. Polio has been eliminated from the United States, but it still occurs in other parts of the world. The best way to protect yourself and keep the United States polio-free is to maintain high immunity (protection) in the population against polio through vaccination.
Related Packages: 50090-1693-09Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Polio Vaccine
Product Information
NDC | 50090-1693 |
---|---|
Product ID | 50090-1693_7be9f1ad-b434-44f4-9a60-6bac86beeacf |
Associated GPIs | 17100050002250 |
GCN Sequence Number | 009648 |
GCN Sequence Number Description | poliomyelitis vaccine, killed VIAL 40-8-32 INJECTION |
HIC3 | W7H |
HIC3 Description | ENTERIC VIRUS VACCINES |
GCN | 43569 |
HICL Sequence Number | 004196 |
HICL Sequence Number Description | POLIOMYELITIS VACCINE, KILLED |
Brand/Generic | Generic |
Proprietary Name | IPOL |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED), POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED), and POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED) |
Product Type | VACCINE |
Dosage Form | INJECTION, SUSPENSION |
Route | INTRAMUSCULAR |
Active Ingredient Strength | 40; 8; 32 |
Active Ingredient Units | [D'ag'U]/.5mL; [D'ag'U]/.5mL; [D'ag'U]/.5mL |
Substance Name | POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED); POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED); POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED) |
Labeler Name | A-S Medication Solutions |
Pharmaceutical Class | Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Actively Acquired Immunity [PE], Inactivated Poliovirus Vaccine [EPC], Inactivated Poliovirus Vaccine [EPC], Inactivated Poliovirus Vaccine [EPC], Poliovirus Vaccines [CS], Poliovirus Vacci |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA103930 |
Listing Certified Through | 2024-12-31 |
Package
NDC 50090-1693-09 (50090169309)
NDC Package Code | 50090-1693-9 |
---|---|
Billing NDC | 50090169309 |
Package | 1 VIAL, MULTI-DOSE in 1 PACKAGE (50090-1693-9) / 5 mL in 1 VIAL, MULTI-DOSE (50090-1693-0) |
Marketing Start Date | 1990-12-21 |
NDC Exclude Flag | N |
Pricing Information | N/A |